Vancouver explores subdividing laneway homes
On Wednesday, council unanimously approved a motion for staff to explore the idea of allowing the subdivision or stratification of laneway homes.
The motion was tabled by ABC councillors Sarah Kirby-Yung and Mike Klassen.
Klassen said there are about 6,000 of these kinds of homes in Vancouver.
'It's really a way to look forward on how we actually use land within our residential neighborhoods,' he said. 'Laneway houses are incredibly popular.'
Klassen added if the idea is adopted, it could provide greater opportunities for intergenerational living.
'I think it will provide real opportunities for more housing, and more people to get into the market and potentially have a better way for people to downsize,' he said.
Industry support
According to the motion, titled 'Opening Doors: Expanding Ownership Options for Laneway and Backyard Homes,' while the city has recently allowed stratification and subdivision for multiplex developments, the same opportunity does not currently apply to laneway homes and accessory dwelling units, 'even when these units meet the siting, massing, and design guidelines of the R1-1 policy.'
Bryn Davidson, the co-owner of Lanefab Design/Build, said his clients have been requesting this option for years.
'Say you're a family,' he said. 'If you're able to separate these into two strata units, then your kid can get their own mortgage. They can sell the house if they need to when it's time to inherit the the property. It's easier to deal with. So it just makes everything a lot simpler.'
'Financial barriers'
Akua Schatz, the board chair of Small Housing B.C. and owner of Smallworks Studios, agreed with Davidson, adding she wished she had this option when her family built one of the first laneway homes in North Vancouver in 2010.
'We were hoping that strata titling would come into place just to help to ease some of the legal and financial barriers that we were facing, trying to create a co-ownership model that worked,' she said.
Schatz said Small Housing B.C. conducted a poll on the public's attitudes around this kind of housing, the results of which were published Thursday.
'They found that over 80 per cent of folks are really supportive of this form of housing, and they want to see more options in their communities,' she said.
Affordability?
Andy Yan, the director of the city program at Simon Fraser University, said if the city endorses this approach, it may not necessarily address affordability.
'I think that part of this, actually, one has to keep an eye on is really some concerns around speculation,' he said. 'Does this create the latest and newest investment vehicle in Vancouver real estate as opposed to homes for families?'
The staff report is expected to come back to council in the fall or early next year.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
National Post
10 minutes ago
- National Post
WELL Health to Announce Second Quarter 2025 Financial Results on August 14, 2025
Article content VANCOUVER, British Columbia — WELL Health Technologies Corp. (TSX: WELL) (OTCQX: WHTCF) ('WELL' or the 'Company'), a digital healthcare company focused on positively impacting health outcomes by leveraging technology to empower healthcare practitioners and their patients globally, is pleased to announce that the Company will release its Fiscal Second Quarter 2025 financial results for the period ended June 30, 2025, before the market opens on Thursday, August 14, 2025. The Company will hold a conference call and simultaneous webcast to discuss its results on the same day at 1:00 pm ET (10:00 am PT). The call will be hosted by Hamed Shahbazi, Chairman and Chief Executive Officer and Eva Fong, Chief Financial Officer. Please dial in 10 minutes prior to the start of the call. Article content Conference Call Participant Details Article content Date: Thursday, August 14, 2025 Article content Time: 1:00 PM ET / 10:00 AM PT Article content International Toll: 289-514-5100 Article content North American Toll Free: 1-800-717-1738 Article content To attend the webcast, register now or visit for details. Article content WELL HEALTH TECHNOLOGIES CORP. Article content Per: 'Hamed Shahbazi' Hamed Shahbazi Chief Executive Officer, Chairman and Director WELL Health Technologies Corp. Article content About WELL Health Technologies Corp. Article content WELL's mission is to tech-enable healthcare providers. We do this by developing the best technologies, services, and support available, which ensures healthcare providers are empowered to positively impact patient outcomes. WELL's comprehensive healthcare and digital platform includes extensive front and back-office management software applications that help physicians run and secure their practices. WELL's solutions enable more than 42,000 healthcare providers between the US and Canada and power the largest owned and operated healthcare ecosystem in Canada with more than 210 clinics supporting primary care, specialized care, and diagnostic services. In the United States, WELL's solutions are focused on specialized markets such as the gastrointestinal market, women's health, primary care, and mental health. WELL is publicly traded on the Toronto Stock Exchange under the symbol 'WELL' and on the OTC Exchange under the symbol 'WHTCF'. To learn more about the Company, please visit: Article content Article content Article content Article content Contacts Article content Article content Article content Article content
National Post
10 minutes ago
- National Post
Quanterix Launches Novel p-Tau 205 and p-Tau 212 Assays to Advance Alzheimer's Research at AAIC
Article content Company highlights expanded capabilities following Akoya Biosciences Acquisition and Simoa ® technology included in more than 55 posters and oral presentations at the annual conference demonstrating its impact on neurodegenerative disease research Article content BILLERICA, Mass. — Quanterix Corporation (NASDAQ: QTRX), a company fueling scientific discovery through ultrasensitive biomarker detection, today announced the first to market, commercial launch of two novel phospho-tau assays: p‑Tau 205 and p‑Tau 212, expanding its market-leading portfolio of blood-based biomarkers for Alzheimer's disease and neurodegeneration. The announcement comes alongside Quanterix's robust presence at the Alzheimer's Association International Conference (AAIC) 2025, with more than 55 posters and presentations featuring data generated using its Simoa ® technology. Article content These new assays enable the precise detection of tau phosphorylation sites, biomarkers increasingly associated with early and progressive stages of Alzheimer's disease. Developed on Quanterix's ultra-sensitive Simoa ® platform, our p‑Tau 205 and 212 assays empower researchers to explore novel disease mechanisms, refine patient stratification, and support therapeutic development through fluid-based biomarkers. Article content Quanterix's growing leadership in neurobiology was further reinforced by its recent acquisition of Akoya Biosciences, bringing advanced spatial proteomics into its scientific ecosystem. The Human FFPE Neurobiology Panel, originally developed by Akoya, complements the Simoa ® platform by enabling high-plex, spatially resolved analysis of disease-specific protein expression in brain tissue. Together, these platforms offer researchers a powerful combination of tissue- and fluid-based biomarker discovery to accelerate translation from bench to bedside. Article content 'The addition of p‑Tau 205 and 212 strengthens our ability to support the scientific community in its pursuit of earlier detection, deeper understanding, and more personalized treatment approaches for Alzheimer's,' said Masoud Toloue, PhD, CEO of Quanterix. 'Combined with the recent integration of Akoya's spatial biology platform, we are now uniquely positioned to offer researchers a multi-dimensional view of pathobiology—bridging the gap between soluble protein dynamics and spatial tissue context. By uniting two best-in-class technologies, we're advancing the future of precision diagnostics across neurology, oncology, and immunology.' Article content The newly launched p-Tau 205 and p-Tau 212 assays are now available to customers for use on the HD-X or SR-X instruments or testing directly through Quanterix's in-house Accelerator Lab, a CLIA-licensed, ISO 15189-accredited facility providing contract biomarker testing services to global partners in pharma, biotech, and academia. Article content To learn more about the new assays or Quanterix's expanded capabilities, visit or stop by the Quanterix booth at AAIC 2025. Article content About Quanterix Article content Quanterix is a global leader in ultra-sensitive biomarker detection, enabling breakthroughs in disease research, diagnostics, and drug development. Its proprietary Simoa ® technology delivers industry-leading sensitivity, allowing researchers to detect and quantify biomarkers in blood and other fluids at concentrations far below traditional limits. With more than 3,400 peer-reviewed publications, Quanterix has been a trusted partner to the scientific community for nearly two decades. In 2025, Quanterix acquired Akoya Biosciences, The Spatial Biology Company ®, adding multiplexed tissue imaging with single-cell resolution to its portfolio and 1,396 installed instruments. Together, the combined company offers a uniquely integrated platform that connects biology across blood and tissue—advancing precision medicine from discovery to diagnostics. Learn more at Article content Article content Article content Article content Contacts Article content Media Contact: Marissa Klaassen (781) 913.8036 media@ Article content
Globe and Mail
10 minutes ago
- Globe and Mail
Leveraged ETFs take off in Canada, but hold on tight
Retail investors are increasingly turning to Canadian leveraged exchange-traded funds to weather – and even benefit from – the market volatility of on-again, off-again U.S. tariffs and threats. Leveraged ETFs have become the fastest-growing ETF category in the country as investors appear to be hungry for big returns and willing to accept the corresponding higher risks. In June, Canadian leveraged and inverse ETFs received $432-million in inflows, the highest percentage growth among all ETF asset classes in the country, according to a report by National Bank Financial. Leveraged ETFs use the power and complexity of derivatives, including total return swaps, futures and options to amplify performance. The funds can magnify gains or losses by two or three times compared with actual market returns. Inverse ETFs bet that a particular market or asset will fall. These specialized funds are inherently tactical and they are intended to be owned for only a few hours or days, at maximum, to take advantage of short-lived market conditions such as interest-rate announcements, economic data, or bellwether earnings reports, says Steve Hawkins, CEO of LongPoint ETFs. Heightened market volatility is one of the key drivers behind the popularity of leveraged funds, but they are best suited to moderate – not extreme – unpredictability, says Raghav Mehta, vice-president and ETF strategist with Global X Investments Canada Inc., which offers more than 32 leveraged ETFs through its BetaPro series. 'When the markets are clearly trending up, or clearly trending down smoothly, that's when the [leveraged] ETFs compound favourably over a couple of days,' Mr. Mehta says. 'We don't want to be owning these products when markets are super choppy and super volatile.' Owners of leveraged ETFs do not buy and hold, he adds. 'I like to call them 'traders' more than 'investors.' They are like speculators.' Toronto-based LongPoint and BetaPro lead the leveraged ETF category in Canada and they are beefing up their exposures in hopes of satisfying Canadian investors who previously sought out U.S. leveraged funds because of limited selection at home. According to LongPoint, there are 196 leveraged and inverse-leveraged exchange-traded products listed in the United States that track equity and fixed income indices, including 75 triple-leveraged (or higher) index funds. By contrast, Canada has a small fraction of that number, though it is growing. 'The big thing we are trying to do is repatriate Canadian investors to using Canadian ETFs versus going south of the border to use U.S. ETFs,' Mr. Hawkins says. Home-grown leveraged ETFs sidestep the tax, currency and administrative headaches for Canadian investors who used to seek out U.S. counterparts. Interest in higher-risk products is increasing. An Angus Reid Forum survey conducted for BetaPro late last year found that 27 per cent of more than 1,000 respondents said they would consider taking more investment risks, with 12 per cent interested in leveraged ETFs. The younger the investor, the higher the appetite for risk. 'We are now seeing a lot of people using these products and that is why issuers like us and others in the marketplace want to respond to this demand by launching more of these products,' Mr. Mehta says. These vehicles are predominately utilized by active investors who are looking for sophisticated investment strategies with reduced risk, Mr. Hawkins says. He described them as a 'one-ticket solution without having margin accounts, without having to deal with futures, without having to do all the inner workings to have your own leveraged exposure.' The investor's potential loss 'is limited to your initially invested principal,' Mr. Hawkins adds. 'You can't lose more, whereas with a future you can potentially lose more than what margin you put up.' That built-in sophistication and the daily adjustments come with sharply higher fees. Most leveraged ETFs charge 1.55 per cent of net asset value, compared with management-expense ratios for typical ETFs starting at 0.03 per cent and rising to 1 per cent for actively managed funds. But Mr. Hawkins points out that the heftier fee for leveraged funds works out to pennies when the products are held short term as intended, potentially worth the price for what would otherwise be a complex investment for a do-it-yourselfer.
